539
Views
12
CrossRef citations to date
0
Altmetric
Review

Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

Pages 323-332 | Received 01 Feb 2018, Accepted 19 Mar 2018, Published online: 02 Apr 2018

References

  • Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care. 2007;13(Suppl):1–12.
  • Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35(Suppl):S61–S66.
  • Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199–204.
  • Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13:1599–1613.
  • ANI Pharmaceuticals. REGLAN (metoclopramide) tablets, for oral use. Prescribing information. [update Aug 2017; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017854s062lbl.pdf
  • Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264–e278.
  • Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39–48.
  • Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69:978–997.
  • Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541–547.
  • Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160:1117–1124.
  • Stahl SM. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects. CNS Spectr. 2017 Dec 18:1–6. Epub ahead of print. DOI: 10.1017/S1092852917000621.
  • Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia: promising leads and ways forward. J Neurol Sci. [2018 Feb 5]  Epub ahead of print. DOI: 10.1016/j.jns.2018.02.011.
  • Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976.
  • Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39:1172–1177.
  • Neurocrine Biosciences. INGREZZA (valbenazine) capsules, for oral use. Prescribing information.[updated 2017 Oct; cited 2018 Jan 26]. Available from: https://ingrezza.com/HCP/PI
  • Teva Pharmaceuticals. AUSTEDO (deutetrabenazine) tablets, for oral use. Prescribing information. [update 2017 Aug; cited 2018 Jan 26]. Available from: https://www.austedo.com/hd/pi
  • Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71:e12964.
  • Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71:e13030.
  • Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487.
  • Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999;20:269–275.
  • Merck. COGENTIN (benztropine mesylate injection). Prescribing information. [update 2013 Apr; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s026lbl.pdf
  • Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 17;1:CD000204.
  • Vinogradov S, Fisher M, Warm H, et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055–1062.
  • Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136–1147.
  • Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703–714.
  • Roth LS. Tarvil for tardive dyskinesia: are we robbing Peter to pay Paul? Federal Practitioner. 2004;21(11):48, 53, 56–62.
  • Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–469.
  • Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445–451.
  • Zheng W, Xiang YQ, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107–111.
  • Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–275.
  • Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.
  • Endo Pharmaceuticals. SYMMETREL (Amantadine Hydrochloride, USP) tablets and syrup prescribing information. [update 2009 Jan; cited 2018 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf
  • Adamas Pharma. GOCOVRI (amantadine) extended release capsules, for oral use. Prescribing information. [update 2017 Aug; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208944lbl.pdf
  • Lundbeck. XENAZINE (tetrabenazine) tablets, for oral use. Prescribing information. [update Jun 2015; cited 2018 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021894s010lbl.pdf
  • Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016;21(S1):13–24.
  • Chandler JH. Reserpine in the treatment of Huntington’s chorea. Med Bull (Ann Arbor). 1955;21:95–100.
  • Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996;93:5166–5171.
  • German CL, Baladi MG, McFadden LM, et al. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol Rev. 2015;67:1005–1024.
  • Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014;73:89–97.
  • Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959;127:103–109.
  • Brandrup E. Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am J Psychiatry. 1961;118:551–552.
  • Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia, I: clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972;27:95–99.
  • Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130:479–483.
  • Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–1281.
  • Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331–373.
  • Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487–1504.
  • Prestwick Pharmaceuticals. Briefing document for Peripheral and Central Nervous System Advisory Committee. [2007 Dec 6 and revised 2007 Nov 9; cited 2018 Mar 17]. Available from: https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4328b1-02-Prestwick.pdf
  • Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454–461.
  • Skor H, Smith EB, Loewen G, et al. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17:449–459.
  • Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.
  • Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year kinect 3 extension study. J Clin Psychiatry. 2017;78:1344–1350.
  • O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.
  • Thai-Cuarto D, O’Brien CF, Jimenez R, et al. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2017 Dec 7. Epub ahead of print. DOI: 10.1007/s40264-017-0623-1.
  • Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010.
  • Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595–604.
  • Anderson K, Stamler D, Davis M, et al. Deutetrabenazine for the treatment of tardive dyskinesia: results from an open-label, long-term study. Poster Presentation P7-009. The American Psychiatric Association 2017 Annual Meeting; San Diego, California, 2017 May 20-24.
  • Anderson K, Stamler D, Davis M, et al. Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: results from an open-label, long-term study. Mov Disord. 2017;32:S1578.
  • Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917–1928.
  • Institute for Clinical and Economic Review. A Look at VMAT2 inhibitors for tardive dyskinesia. [2017 Dec; cited 2018 Feb 1]. Available from: https://icer-review.org/wp-content/uploads/2017/12/icer_tardive-dyskinesia_RAAG-122217.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.